Friday, 16 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 13, 2026

Can Strong iPhone and Mac Portfolio Help Apple Stock Recover in FY26?

View original at finance.yahoo.com
Can Strong iPhone and Mac Portfolio Help Apple Stock Recover in FY26? Apple AAPL shares have dropped 4.2% year to date (YTD), outperforming close peers such as HP HPQ and Microsoft MSFT but lagging Amazon AMZN…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Global smartphone shipments declined 6% year over year in the first quarter of 2026, with Apple leading with 21% market share and shipments growing 5% year over year, driven by strong iPhone 17 demand and improved performance in China

    60% confidence

  • Worldwide PC shipments totaled 62.8 million units in the first quarter of 2026, up 4% year over year

    60% confidence

  • Lenovo led PC market with 26.5% market share, trailed by HP and Dell Technologies with 19.3% and 16.5%, respectively. Apple had a 10.6% market share

    60% confidence

  • The Zacks Consensus Estimate for Apple's fiscal 2026 revenues is pegged at $461.68 billion, indicating 10.94% growth over fiscal 2025

    60% confidence

  • Apple shares are overvalued, as suggested by a Value Score of F

    60% confidence

  • The Zacks Consensus Estimate for Apple's fiscal 2026 earnings is $8.40 per share, indicating 12.6% growth from fiscal 2025

    60% confidence

  • Samsung's shipments declined 6% year over year with 20% market share

    60% confidence

Data points we hold from this source

HP Inc. · market share19.3 percent
HP Inc. · pe ratio6.37 ratio
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com
Can Strong iPhone and Mac Portfolio Help Apple Stock Recover in FY26? — Source | Via News | ViaNews EU